Saturday, February 24, 2018 The New England Journal of Medicine Feb. 22 published data for larotrectinib in the treatment of pediatric and adult patients whose tumors harbor tropomyosin receptor kinase gene fusions. Senior study author, MSK’s David Hyman is featured.